Alzamend Neuro, Inc. · NASDAQ:ALZN

Alzamend Neuro, Inc. financial statements

Alzamend Neuro, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020
Research and development3.63M1.41M6.46M7.45M5.20M1.31M1.07M
Operating income-8.77M-4.50M-9.94M-14.9M-12.3M-4.95M-4.42M
Depreciation and amortization110.7K50.7K50.7K23.1K3.55K
EBITDA-8.66M-4.45M-9.89M-14.8M-12.3M
Interest expense6.62K18.0K10.1K7.70K46.5K142.4K
Income before tax-8.77M-4.51M-9.95M-14.9M-12.4M-5.05M-4.41M
Net income-8.77M-4.51M-9.95M-14.9M-12.4M-5.05M-4.41M
Earnings per share, basic-2.63-11.32-132.33-22.89-0.14-0.07-0.06
Earnings per share, diluted-2.63-11.32-132.33-22.89-0.14-0.07-0.06

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents710.7K3.95M376.0K5.14M14.1M1.93M90.3K
Current assets1.76M4.18M455.2K5.84M14.4M2.91M1.81M
Property, plant and equipment314.9K425.6K176.3K79.8K102.9K
Total assets2.08M4.60M631.6K5.92M14.5M2.91M1.81M
Accounts payable2.93M2.87M1.16M503.6K929.6K
Current liabilities2.87M1.16M899.6K992.3K
Total liabilities1.35M634.8K3.23M2.87M1.16M899.6K
Shareholders' equity733.2K3.97M-2.59M3.05M13.4M2.01M821.7K
Shares outstanding4.26M778.7K76.4K646.3K95.5M67.4M64.8M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-8.07M-6.57M-8.27M-8.92M-6.61M-2.71M-2.35M
Cash from investing-300.0K-147.2K-106.5K100.9K105.0K
Cash from financing4.83M10.4M3.65M20018.9M4.45M2.29M
Change in cash-3.24M3.57M-4.76M-8.92M12.1M